X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2024/03/06/2841290/35186/en/Kura-Oncology-Reports-First-Patient-Dosed-in-Trial-of-KO-2806-Plus-Cabozantinib-in-Renal-Cell-Carcinoma.html
https://endpts.com/roche-and-exelixis-detail-rare-success-for-cabometyx-tecentriq-combo-in-prostate-cancer/
https://www.globenewswire.com//news-release/2024/01/22/2813509/0/en/Latest-Phase-III-trial-data-investigating-Cabometyx-in-combination-with-immunotherapy-to-be-presented-at-ASCO-GU-2024.html
https://ir.exelixis.com/news-releases/news-release-details/detailed-results-phase-3-cabinet-pivotal-trial-evaluating
https://www.fiercepharma.com/pharma/exelixis-cabometyx-trial-wraps-early-after-proving-dramatic-improvement-pancreatic-tumors#:~:text=It's%20not%20always%20a%20good,of%20an%20undeniable%20efficacy%20showing.
https://endpts.com/exelixis-teva-reach-settlement-on-cabometyx-patent-dispute/
https://www.fiercepharma.com/pharma/roche-exelixis-tecentriq-cabometyx-pair-fails-again-time-kidney-cancer
https://www.globenewswire.com/news-release/2023/02/13/2607166/30446/en/Aravive-to-Present-Positive-Updated-Data-from-Phase-1b-Trial-of-Batiraxcept-in-Combination-with-Cabozantinib-for-Treatment-of-Clear-Cell-Renal-Cell-Carcinoma-at-the-2023-ASCO-Genit.html
https://www.biospace.com/article/exelixis-roche-combo-fails-to-improve-overall-survival-in-nsclc-/
https://www.fiercepharma.com/pharma/exelixis-axes-plan-cabometyx-combo-roches-tecentriq-after-late-stage-liver-cancer-study
https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-enrollment-completion-phase-3-contact-01
https://www.pharmatimes.com/news/smc_accepts_cabometyxopdivo_combo_for_advanced_kidney_cancer_patients_1380746
https://www.fiercepharma.com/pharma/ipsen-poaches-novartis-vet-mari-scheiffele-to-serve-as-president-its-international-specialty
https://www.pharmatimes.com/news/fda_approves_exelixis_cabometyx_for_differentiated_thyroid_cancer_1378154
https://www.fiercepharma.com/pharma/esmo-exelixis-lays-out-promising-cabometyx-combo-data-prostate-cancer-but-key-discrepancies
https://www.businesswire.com/news/home/20210607005127/en/Exelixis-and-Ipsen-Announce-Detailed-Results-from-Phase-3-COSMIC-311-Pivotal-Trial-of-Cabozantinib-in-Patients-with-Previously-Treated-Radioactive-Iodine-Refractory-Differentiated-Thyroid-Cancer-Presented-at-ASCO-2021
https://www.globenewswire.com/news-release/2021/06/07/2242678/32478/en/Final-Data-from-Calithera-Biosciences-Phase-2-CANTATA-Study-in-Renal-Cell-Carcinoma-Presented-at-2021-ASCO-Annual-Meeting.html
https://www.ipsen.com/press-releases/ipsen-opts-in-to-join-exelixis-with-ongoing-development-of-cabometyx-for-people-living-with-a-form-of-thyroid-cancer-based-on-promising-interim-results/
https://www.pharmtech.com/view/ec-approves-bms-opdivo-in-combination-with-cabometyx-for-advanced-rcc
https://endpts.com/glaxosmithkline-offloads-royalty-rights-for-2-cancer-drugs-in-342m-windfall-it-will-use-to-finance-consumer-spinoff/
http://www.globenewswire.com/news-release/2021/04/01/2203200/0/en/Royalty-Pharma-Acquires-Royalty-Interest-in-Cabozantinib-From-GSK.html
https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-enrollment-completion-phase-3-cosmic-313
Market Place
Share 
